About US
Contact us
-
Swiss insurer jumps into legal fight over Bayer's YasminBayer has another foe in its battle to defend the contraceptive pill Yasmin. Switzerland's biggest insurer, CSS, is backing a woman's claims against the German company, joining in her lawsuit that al2013/1/10
-
China hits Big Pharma meds with 15%-plus price cutsPharma's path to a big payoff in China is growing narrower and narrower. The government has just announced its fourth drug-price cut since 2011, with 400 meds subject to forced discounts. And on that2013/1/9
-
Ethris Announces Research Based Alliance on SNIM® Modified RNA with ShireEthris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. Many devastating human diseases2013/1/9
-
Roche chairman pooh-poohs another Illumina bidIf you've been rooting for Roche ($RHHBY) to make another run at the gene sequencing company Illumina ($ILMN), you could be in for a disappointment. The drugmaker's chairman, Franz Humer, told a Swis2013/1/8
-
Takeda, Affymax nail supply deal for Omontys anemia drugTakeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to tre2013/1/8
-
Evotec Acquires Cell Culture ServiceEvotec AG has acquired Cell Culture Service GmbH (CCS), based in Hamburg, Germany, for $1.5 million in cash and an earn-out payment of $1.4 million in cash. CCS supplies custom cells and cell-based r2013/1/7
-
NGM, Janssen in Diabetes Discovery AllianceNGM Biopharmaceuticals has signed a worldwide agreement with Janssen Pharmaceuticals to discover and develop therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases.2013/1/7
-
AstraZeneca in Discovery Pact with Cellular DynamicsCellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and t2013/1/6
-
AbbVie Launches New Biopharma CompanyAbbVie has launched as an independent biopharmaceutical company, as Abbott completed the separation from the research arm of its pharmaceutical business. AbbVie launches with an estimated $18 billion2013/1/6
-
India set to rule in Novartis patent caseIndia's Supreme Court is expected to rule soon on a patent for Novartis' ($NVS) groundbreaking cancer treatment Gleevec, and Big Pharma and international aid groups are waiting with bated breath to s2013/1/5